DZ Bank restated their neutral rating on shares of Merck KGaA (FRA:MRK) in a research report report published on Tuesday, April 2nd, Borsen Zeitung reports.
Other analysts also recently issued research reports about the company. Kepler Capital Markets set a €108.00 ($125.58) price target on Merck KGaA and gave the stock a buy rating in a research note on Wednesday, December 12th. Societe Generale set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the stock a neutral rating in a research report on Wednesday, March 27th. JPMorgan Chase & Co. set a €100.00 ($116.28) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Tuesday, January 8th. Sanford C. Bernstein set a €105.00 ($122.09) price objective on shares of Merck KGaA and gave the company a buy rating in a report on Thursday, February 28th. Finally, Morgan Stanley set a €88.00 ($102.33) price objective on shares of Merck KGaA and gave the company a neutral rating in a report on Friday, December 14th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of Hold and an average price target of €100.95 ($117.38).
Shares of FRA:MRK traded up €0.50 ($0.58) on Tuesday, reaching €95.62 ($111.19). 501,912 shares of the company’s stock were exchanged. Merck KGaA has a fifty-two week low of €76.60 ($89.07) and a fifty-two week high of €115.00 ($133.72).
MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.
See Also: Google Finance Portfolio Workaround
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.